A review of methods for detect human Papillomavirus infection

Virology Journal

Marcia E L Consolaro¹  Fabrícia Gimenes¹  Raquel P Souza¹  André L P Abreu¹ 

[1]Division of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, Av. Colombo 5790, 87020-900, Paraná, Brazil

关键词: Cervical lesions progression;    Cervical cancer;    Biomarkers;    Detection methods;    Human Papillomavirus;   

Others  :  1153277
DOI  :  10.1186/1743-422X-9-262

 received in 2012-03-31, accepted in 2012-11-02,  发布年份 2012

【 摘 要 】

Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops over a long period through precursor lesions, which can be detected by cytological screening. Although this screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of women with HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related biomarkers, a variety of methods are being developed for these purposes. This review summarizes current knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a high risk of progression to CC.

【 授权许可】

   
2012 Abreu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010, 117(Suppl 2):5-10.
• [2]Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of Papillomavirus (HPV) and its relation with cervical cancer. Virol J 2011, 8:269. BioMed Central Full Text
• [3]de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur H: Classification of papillomaviruses. Virology 2004, 324:17-27.
• [4]IARC: Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007, 90:1-636.
• [5]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.: WHO International Agency for WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens- Part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [6]Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, et al.: Human papillomavirus subtype 16 is common in Pakistaniwomen with cervical carcinoma. Int J Infect Dis 2007, 11:313-317.
• [7]Sheng J, Zhang WY: Identification of biomarkers for cervical cancer in peripheral blood lymphocytes using oligonucleotide microarrays. Chin Med J 2010, 123:1000-1005.
• [8]Termini L, Villa LL: Biomarkers in screening of Cervical Cancer. J Bras Doenças Sex Trasm 2008, 20:125-131.
• [9]Wentzensen N, Klug SJ: Cervical cancer control in the era of HPV vaccination and novel biomarkers. Pathobiology 2009, 76:82-89.
• [10]Chow LT, Broker TR, Steinberg BM: The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010, 118:422-449.
• [11]Villa LL, Denny L: Methods for detection of HPV infection and its clinical utility. Int J Gyn Obst 2006, 94:71-80.
• [12]Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al.: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26:29-41.
• [13]Pannier-Stockman C, Segard C, Bennamar S, Gondry J, Boulanger JC, Sevestre H, et al.: Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol 2008, 42:353-360.
• [14]Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human Papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
• [15]Forinash AB, Yancey AM, Pitlick JM, Myles TD: Safety of the HPV bivalent and quadrivalent vaccines during pregnancy (february). Ann Pharmacother 2011, 45:258-262.
• [16]Merck : Broad spectrum HPV (Human Papillomavirus) vaccine study in 16-to 26-Year-Old Women (V503-001). http://clinicaltrials.gov/ct2/show/NCT00543543 webcite. Acessed in March 20, 2011
• [17]Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, et al.: Costa Rica HPV vaccine trial (CVT) group: determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010, 10:238.
• [18]Shen-Gunther J, Yu X: HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecol Oncol 2011, 123:263-271.
• [19]Hwang SJ, Shroyer KR: Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012., 507286Epub 2011 Oct 29
• [20]Bozzetti M, Nonnenmacher B, Mielzinska II, Villa L, Lorincz A, Breitenbach VV, et al.: Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann Epidemiol 2000, 10:466.
• [21]Wright TC Jr, Schiffman M: Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003, 348:489-490.
• [22]Frazer IH, Leggatt GR, Mattarollo SR: Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 2011, 29:111-138.
• [23]Otero-Motta AP, Ordóñez JL, González-Celador R, Rivas B, Macías M, Macías MC, et al.: Prevalence of human papillomavirus genotypes in cytologic abnormalities from unvaccinated women living in north-western Spain. APMIS 2011, 119:204-215.
• [24]Johnson LR, Starkey CR, Palmer J, Taylor J, Stout S, Holt S, et al.: A comparasion of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol 2008, 130:401-408.
• [25]Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al.: Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010, 118:116-122.
• [26]Bartholomew DA, Luff RD, Quigley NB, Curtis M, Olson MC: Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples. J Clin Virol 2011, 51:38-43.
• [27]Rahman M, Sasagawa T, Yamada R, Kingoro A, Ichimura H, Makinoda S: High prevalence of intermediate-risk human papillomavirus infection in uterine cervices of kenyan women infected with human immunodeficiency virus. J Med Virol 2011, 83:1988-1996.
• [28]Hoheisel JD: Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 2006, 7:200-210.
• [29]Brandstetter T, Böhmer S, Prucker O, Bissé E, zur Hausen A, Alt-Mörbe J, et al.: A polymerase based DNA biochip platform for human papillomavirus genotyping. J Virol Methods 2010, 163:40-48.
• [30]Didelot MN, Boulle N, Damay A, Costes V, Segondy M: Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes. J Med Virol 2011, 83:1377-1382.
• [31]Pista A, Verdasca N, Oliveira A: Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol 2011, 83:272-276.
• [32]Bryant D, Rai N, Rowlands G, Hibbitts S, Jones J, Tristram A, et al.: Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA microarray. J Med Virol 2011, 83:1358-1361.
• [33]Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kjaer SK, et al.: Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 2010, 82:605-615.
• [34]Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C: Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of papillomavirus in cervical and anal scraps. J Med Virol 2011, 83:1377-1382.
• [35]Barcellos RB, Almeida SE, Sperhacke RD, Verza M, Rosso F, Medeiros RM, et al.: Evaluation of a novel microplate colorimetric hybridization genotyping assay for human papillomavirus. J Virol Methods 2011, 77:38-43.
• [36]Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA: Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009, 24:215-222.
• [37]Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M, et al.: Detection by HPV of human papillomavirus in Colombia: comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods 2011, 178:68-74.
• [38]Coser J, Boeira TR, Fonseca AS, Ikuta N, Lunge VR: Human papillomavirus detection and typing using a nested-PCR-RFLP assay. Braz J Infect Dis 2011, 15:467-472.
• [39]Carvalho NO, del Castillo DM, Perone C, Januário JN, Melo VH, Brasileiro Filho G: Comparison of HPV genotyping by type-specific PCR and sequencing. Mem Inst Oswaldo Cruz 2010, 105:73-78.
• [40]Nogara PR, Gimenes F, Consolaro ME: Distribution of HPV genotypes and HPV-16 and HPV-18 E2 gene disruption in South Brazilian women with cervical abnormalities. Int J Gynaecol Obstet 2012.
• [41]Maver PJ, Poljak M, Seme K, Kocjan BJ: Detection and typing of low-risk human papillomavirus genotypes HPV 6, HPV 11, HPV 42, HPV 43 and HPV 44 by polymerase chain reaction and restriction fragment length polymorphism. J Virol Methods 2010, 169:215-218.
• [42]Naqvi SH, Wajid S, Mitra AB: Restriction fragment length polymorphism of L1 amplificon using RSA 1 detects five different human papillomavirus types and their co-infections among women attending a gynaecological outpatient department. J Virol Methods 2004, 117:91-95.
• [43]Santiago E, Camacho L, Junquera ML, Vázquez F: Full HPV typing by a single restriction enzyme. J Clin Virol 2006, 37:38-46.
• [44]Kocjan BJ, Seme K, Poljak M: Comparison of the Abbott Real Time High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. J Virol Methods 2011, 175:117-119.
• [45]Roberts I, Ng G, Foster N, Stanley M, Herdman MT, Pett MR, et al.: Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol 2008, 8:57. BioMed Central Full Text
• [46]Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al.: Clinical validation of the Cobas 488 HPV test for cervical screening purposes. J Clin Microbiol 2011, 49:3983-3985.
• [47]Mateos ML, Rodríguez-Domínguez M, Sanz I, Rubio MD, Antonio J, Chacón D: Evaluation of a prototype real-time PCR assay for the separate detection of human papillomavirus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening. Enferm Infecc Microbiol Clin 2011, 29:411-414.
• [48]Martínez SB, Palomares JC, Artura A, Parra M, Cabezas JL, Romo JM, et al.: Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J Virol Methods 2012, 180:7-10.
• [49]Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Biotechnology 1992, 24:104-108.
• [50]Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, et al.: Fluorescence detection in automated DNA sequence analysis. Nature 1986, 321:674-679.
• [51]Lee LG, Connell CR, Woo SL, Cheng RD, McArdle BF, Fuller CW, et al.: DNA sequencing with dye-labeled terminators and T7 DNA polymerase: effect of dyes and dNTPs on incorporation of dye-terminators and probability analysis of termination fragments. Nucleic Acids Res 1992, 20:2471-2483.
• [52]Novais RC, Thorstenson YR: The evolution of Pyrosequencing® for microbiology: from genes to genomes. J Microbiol Methods 2011, 86:1-7.
• [53]van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ: Evaluation of the SPF10-Inno LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 2006, 44:3122-3129.
• [54]Sukasem C, Pairoj W, Saekang N, Pombubpha H, Srichunrasami C, Pongtippan A, Junyangdikul P, Chantratita W: Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J Med Virol 2011, 83:119-126.
• [55]Lenselink CH, de Bie RP, van Hamont D, Bakkers JM, Quint WG, Massuger LF, et al.: Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by the FTA cartridge: new possibilities for cervical screening. J Clin Microbiol 2009, 47:2564-2570.
• [56]Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ: The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011, 21:139-153.
• [57]Dobec M, Bannwart F, Kilgus S, Kaeppeli F, Cassinotti P: Human papillomavirus infection among women with cytological abnormalities in Switzerland investigated by an automated linear array genotyping test. J Med Virol 2011, 83:1370-1376.
• [58]Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, et al.: Low- level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J Med Virol 2011, 83:1362-1369.
• [59]Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al.: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
• [60]Rosenblatt C, Wroclawski ER, Lucon AM, Pereyra EAG: HPV in Clinical Practice. Atheneu, São Paulo; 2005:25-37.
• [61]Wentzensen N, von Knebel DM: Biomarkers in cervical cancer screening. Dis Markers 2007, 23:315-330.
• [62]Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, et al.: Analytical characterization of the APTIMA HPV Assay. J Clin Virol 2009, 45(Suppl 1):39-47.
• [63]Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008, 17:2536-2545.
• [64]Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafken PR, Galloway DA: NFX1-123 and poly (A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing Cells. J Virol 2007, 81:3786-3796.
• [65]Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al.: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
• [66]Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, Tomaic V, et al.: The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 2005, 280:10807-10816.
• [67]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [68]de Wilde J, Wilting SM, Meijer CJ, van de Wiel MA, Ylstra B, Snijders PJ, et al.: Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. Int J Cancer 2008, 122:877-888.
• [69]Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL: Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006, 35:270-277.
• [70]Hesselink AT, van Ham MA, Heideman DA, Groothuismink ZM, Rozendaal L, Berkhof J, et al.: Comparison of GP5+/6+−PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008, 46:3215-3221.
• [71]Xi LF, Koutsky LA, Castle PE, Wheeler CM, Galloway DA, Mao C, et al.: Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2–3. J Natl Cancer Inst 2009, 101:153-161.
• [72]Lowe B, O'Neil D, Loeffert D, Nazarenko I: Distribution of Human papillomavirus load in clinical specimens. J Virol Methods 2011, 173:150-152.
• [73]Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al.: High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts development incident disease. Int J Cancer 2007, 21:2787-2793.
• [74]Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al.: Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int J Gynecol Cancer 2008, 18:121-127.
• [75]Kulmala SM, Syrjänen SM, Gyllensten UB, Shabalova IP, Petrovichev N, Tosi P, et al.: Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006, 59:513-517.
• [76]Dos Santos Oliveira LH, Rodrigues EV, de Salles Lopes AP, Fernandez AP, Cavalcanti SM: HPV 16 detection in cervical lesions, physical state of viral DNA and changes in p53 gene. Sao Paulo Med J 2003, 121:67-71.
• [77]Cricca M, Venturoli S, Leo E, Costa S, Musiani M, Zerbini M: Disruption of HPV 16 and E2 genes in precancerous cervical lesions. J Virol Methods 2009, 158:180-183.
• [78]Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli MR, Vecchione A, Giordano A: Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol 2003, 56:532-632.
• [79]Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, Cheng WF: Integration of human papillomavirus correlates with levels of viral oncogene transcripts in cervical carcinogenesis. Virus Res 2011, 161:124-130.
• [80]Ho CM, Chien TY, Huang SH, Lee BH, Chang SF: Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006, 102:54-60.
• [81]Matovina M, Sabol I, Grubisić G, Gasperov NM, Grce M: Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol Oncol 2009, 113:120-127.
• [82]Jin Y, Li JP, He D, Tang LY, Zee CS, Guo SZ, et al.: Clinical significance of human telomerase RNA gene (hTERC) amplification in cervical squamous cell lesions detected by fluorescence in situ hybridization. Asian Pac J Cancer Prev 2011, 12:1167-1171.